Tmunity Appoints Patrick Gray and Garry Nicholson to its Board of Directors as Independent Directors
PHILADELPHIA--(BUSINESS WIRE)--Feb 14, 2019--Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced the appointments of Patrick Gray and Garry Nicholson to its Board of Directors, serving as independent directors effective immediately.
“I am extremely pleased to welcome Pat and Garry to our Board,” said Usman “Oz” Azam, MD, President, Chief Executive Officer and Chairperson of the Board of Tmunity. “Their distinguished leadership track records in the pharmaceutical and biotech industries, will be invaluable as we advance the development of our novel T cell therapies and progress towards commercialization.”
Mr. Gray, currently Director, Audit Committee Chairman and Member of the Quality and Risk Management Committee for Civitas Solutions, Inc., a leading provider of home- and community-based health and human services, was previously Director and Audit Committee Chairman for Sancilio Pharmaceuticals Company, Inc. (acquired by Micelle Biopharma, Inc.) and Director and Audit Committee Chair of Datto, Inc. (acquired by Vista Equity Partners). Formerly an audit partner at PricewaterhouseCoopers (PwC), Mr. Gray has extensive experience serving the boards and audit committees of his clients, particularly fast-growing technology- and services-based companies, including Biogen, Genzyme, Millipore and Sepracor. Mr. Gray is a Certified Public Accountant and a graduate of the University of Pennsylvania, Wharton School of Business. He is a member of the American College of Corporate Directors and of the National Association of Corporate Directors. Mr. Gray will serve as Tmunity’s Audit Committee Chairman.
“I am honored to join Tmunity’s Board and look forward to contributing to the oversight and governance efforts as the company expands and moves its transformative pipeline through clinical development,” said Patrick Gray. “This is truly an exciting time for Tmunity, which is uniquely positioned to bring value to patients and providers who need new treatment options for devastating diseases.”
During his tenure at Pfizer from 2008 to 2015, Garry Nicholson led the global oncology business as President, Pfizer Oncology. Under his leadership, the company developed and launched the first CDK4/6 inhibitor approved in the U.S. and Europe. While at Pfizer, Mr. Nicholson served on the Board of Directors of the Pfizer Foundation and was a member of the company’s Portfolio, Strategy and Investment Committee. Most recently, he served as President and Chief Executive Officer of XTuit Pharmaceuticals, where he was also a member of the board of directors. He currently serves on the Board of Directors of G1 Therapeutics, Inc., Five Prime Therapeutics, Inc., SQZ Biotechnologies and Personal Genome Diagnostics. His board service at TESARO, Inc. lasted from 2015 until the company was acquired by GSK in 2019. Mr. Nicholson holds an MBA from the University of South Carolina, Columbia and a BSc in Pharmacy from the University of North Carolina, Chapel Hill.
“I am excited to work alongside an esteemed board of directors and leadership team with a mission to change the course of cancer treatment,” said Garry Nicholson. “It is truly a privilege to join the Tmunity Board as the company advances towards medical and commercial success.”
About Tmunity Therapeutics
Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190214005254/en/
Chief Financial Officer
Mike Beyer, Sam Brown Inc.
KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Tmunity Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 02/14/2019 08:00 AM/DISC: 02/14/2019 08:01 AM